BlackRock’s Rapport Therapeutics RAPP Stock Holding History

BlackRock’s Portfolio RAPP Stock Details RAPP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$113M	Buy	2,699,786 +193,831	+8%	+$7.12M	﹤0.01%	2160
2026 Q1	$78.4M	Buy	2,505,955 +74,093	+3%	+$2.08M	﹤0.01%	2254
2025 Q4	$73.8M	Buy	2,431,862 +863,781	+55%	+$23.9M	﹤0.01%	2283
2025 Q3	$46.6M	Buy	1,568,081 +348,880	+29%	+$6.22M	﹤0.01%	2552
2025 Q2	$13.9M	Buy	1,219,201 +51,950	+4%	+$551K	﹤0.01%	3234
2025 Q1	$11.7M	Buy	1,167,251 +410,708	+54%	+$5.33M	﹤0.01%	3232
2024 Q4	$13.4M	Buy	756,543 +180,425	+31%	+$4M	﹤0.01%	3266
2024 Q3	$11.8M	Buy	+576,118	New	+$12.4M	﹤0.01%	3322

Other funds holding RAPP

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

TGV

TRV GP V Boston, Massachusetts $498M AUM 267.53% 1-Year Est. Return

AVM

Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

BlackRock's RAPP Position: Q2 2026 in Review

BlackRock increased its Rapport Therapeutics (RAPP) stake by 7.7% in Q2 2026, buying an estimated $7.12M and bringing the position to 2,699,786 shares worth $113M. The position accounts for ﹤0.01% of the portfolio, ranked #2160.

BlackRock first reported a position in RAPP in Q3 2024 and has held it in 8 quarters since. 161 funds tracked by Wall St. Rank hold RAPP as of Q2 2026.

BlackRock held 2,699,786 shares of Rapport Therapeutics worth $113M as of Q2 2026.
BlackRock bought 193,831 Rapport Therapeutics shares in Q2 2026, an estimated $7.12M.
Rapport Therapeutics made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #2160 holding.
BlackRock first reported a position in Rapport Therapeutics in Q3 2024 and has held it in 8 quarters since.
161 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.